Parkinson's disease Nervous System Diseases Parkinson's disease
Conditions
Interventions
We designed this study as a two-arm experiment with 22 participants with Parkinson's disease (PD) and 22 healthy controls. All participants will be aged 40 years and over, recruited from the local com
Sponsors
University of Illinois at urbana-Champaign
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with Parkinson's disease: 1. Medically stable with diagnosis of PD meeting the UK PD Society Brain Bank Criteria – 2. Modified Hoehn & Yahr stage 1-2 (with unilateral involvement only, unilateral and axial involvement, and bilateral involvement without impairment of balance) in the conventionally defined OFF medication state 3. Has medical clearance form from their physician for participation in the study 4. Onn a stable regimen of PD medication 30 days prior to the initiation of the study and until the completion of the study 5. Willing and able to provide informed consent 6. Aged 40 years and above and up 7. Able to have a caregiver/family member present for OFF-state assessment sessions Control group: No known neuromuscular disorders
Exclusion criteria
Exclusion criteria: 1. Presence of dementia based on a Montreal Cognitive Assessment (MOCA) score <25 2. Diagnosis of comorbid neurological disorder, such as epilepsy 3. History of neurological injury, such as stroke 4. History of brain surgery, such as deep brain stimulation 5. Concurrent severe medical illness that in the opinion of the research team will preclude participation in the study (such illnesses may include, but are not limited to, severe or uncontrolled cardiovascular disease, hypertension, pulmonary disease, or diabetes) 6. Inability to attend and participate in at least seven of the training sessions 7. Uncorrected vision defects, history of retinal disease (e.g. macular degeneration), presence of optic neuropathy due to glaucoma or ischemic optic neuropathy, pseudoexfoliation syndrome, ocular surgery, ocular trauma, visually significant cataract, orbital myositis, blindness or refractive errors outside -5 to +3 D 8. Indication by the participant’s neurologist in the medical release form that testing the participant in the OFF-medication state would put PD participants at significant risk for medical complications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in saccade latency from baseline to after 4 weeks of training | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in number of saccades from baseline to after 4 weeks of training 2. Change in saccade length from baseline to after 4 weeks of training 3. Change in saccade velocity from baseline to after 4 weeks of training | — |
Countries
United States of America
Outcome results
None listed